<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04085666</url>
  </required_header>
  <id_info>
    <org_study_id>CDX6114-002</org_study_id>
    <nct_id>NCT04085666</nct_id>
  </id_info>
  <brief_title>Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)</brief_title>
  <official_title>A Phase 1, Multi-center, Randomized, Double-blind, Placebo-controlled, Cross-over Study to Evaluate the Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of a Single Oral Dose of CDX-6114 in Patients With Phenylketonuria (PKU).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nestlé</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nestlé</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is an international, multi-center, randomized, double-blind, placebo-controlled,
      two-treatment, two-period cross-over study to evaluate the pharmacodynamics, safety,
      tolerability and pharmacokinetics of a single oral dose of CDX-6114 in patients with
      phenylketonuria (PKU).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">August 15, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in concentration of post parandial plasma level of Phe will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1hours, 1.5, 2,4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the postprandial plasma levels of Phe following single does of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in concentration of post parandial plasma level of CA will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1hours, 1.5, 2,4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the postprandial plasma levels of CA following single does of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the peak Phe concentration in Plasma will be summarized by treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Peak Phe plasma concentration follwoing a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the peak CA concentration in Plasma will be summarized by treatment</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Peak CA plasma concentration following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phe Area under the plasma concentration versus time curve (AUC) , over a 5-hour period, following dosing and the standardized breakfast</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the Phe AUC following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <primary_outcome>
    <measure>CA Area under the plasma concentration versus time curve (AUC) , over a 5-hour period, following dosing and the standardized breakfast</measure>
    <time_frame>Within 30 minutes, within 10 minutesand immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood samples will be collected at the following time points to determine the CA AUC following a single, oral dose of CDX-6114</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (AEs) will be measured</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Adverse events monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The serum levels of CDX-6114 will be summarized descriptively over time</measure>
    <time_frame>Within 30 minutes, within 10 minutes and immediately prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8</time_frame>
    <description>Blood will be collected for pharmacokinetic analysis of CDX-6114 at the following time points follwoing a single oral dose of CDX-6114</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in blood pressure measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by blood pressure monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in Heart rate measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Heart rate monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in Respiratory rate measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Respiratory rate monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in body temperature (in Fahrenheit or Celsius) measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by Body temperature monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values and changes from baseline in 12 lead Electrocardiogram (ECG) measurements will be summarized over time for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by 12 lead ECG including P Wave, QRS Complex, QT Interval</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute values of Weight measurements will be summarized over time for each treatment using a weighing scale in Kg or pounds</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1hr, 1.5hr, 2hr, 4hr and 5hr after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by weight monitoring</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute blood composition values and changes from baseline to the last post-dose time-point will be summarized for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by laboratory assessments as Haematology and Coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute urine composition values and changes from baseline to the last post-dose time-point will be summarized for each treatment</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1, 1.5, 2, 4 and 5hours after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by routine urinalysis laboratory assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assesment of the incidence of Treatment-Emergent Antibodies</measure>
    <time_frame>Assesments will be done on day 1 and day 8. Blood will be collected for analysis within 30 minutes prior to dosing on Day 1 and Day 8 and again at the End of Study Visit ( through study completion , an avearge of 8 to 10 weeks)</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by assessment for development of anti-CDX-6114 antibodies</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute values of height measurements will be summarized over time for each treatment using length measurement scale in centimeters or inches</measure>
    <time_frame>Within 30 minutes prior to dosing, and then at 15 minutes, 30 minutes, 1hr, 1.5hr, 2hr, 4hr and 5hr after dosing on both Day 1 and Day 8.</time_frame>
    <description>The safety and tolerability of CDX-6114 following single dose oral administration assesed by height examination using Lenght scale</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Phenylketonuria</condition>
  <arm_group>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to treatment with either CDX-6114 or matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Randomized to treatment with either CDX-6114 or matching Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CDX 6114</intervention_name>
    <description>CDX-6114 for oral administration is formulated in phosphate buffer, which also includes mannitol and poloxamer.The vehicle solution provided is identical to the CDX-6114 oral solution except for the active drug.</description>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Matching Placebo</intervention_name>
    <description>The placebo oral dosing solution will also be supplied as an approximately 240 mL oral solution and will be made up of the phosphate buffer diluent and the caramel flavoring.</description>
    <arm_group_label>1st Confinement Period in Unit</arm_group_label>
    <arm_group_label>2nd Confinement Period in Unit</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion criteria

               1. Male and female patients between the ages of 18 and 55 years (inclusive) with a
                  diagnosis of classical PKU by either a historical blood Phe concentration of &gt;
                  1200 mol/L at any time or a genetic diagnosis of PKU.

               2. Patients capable of following dietary instructions to maintain protein intake
                  stable throughout the study duration based on principal investigator and
                  dietician assessment.

               3. Patients with a blood Phe concentration &lt; 1200mol/L at screening.

               4. Have a body mass index (BMI) between 18.0 and 30.0 kg/m2 inclusive and weigh at
                  least 50 kg and no more than 100 kg inclusive.

               5. Patients must be in good general health, as determined by the PI or delegate,
                  based on a medical evaluation including detailed medical history, full physical
                  examination, including blood pressure and pulse rate measurement, 12-lead
                  electrocardiogram (ECG) and clinical laboratory tests.

               6. Male patients (unless surgically sterilised) and their female spouse/partner(s)
                  who are of childbearing potential:

                    1. Must agree to stay abstinent (where abstinence is the preferred and usual
                       life-style of the patient), starting at screening and continuing throughout
                       the clinical study period, and for 90 days after last study drug
                       administration.

                       Or

                    2. Must be using highly effective contraception starting at screening and
                       continuing throughout the clinical study period, and for 90 days after last
                       study drug administration. Highly effective contraception is defined as
                       follows:

                  i. Injectable or implantable hormones ii. Intrauterine device iii. Surgical
                  sterilisation iv. Sterilisation implant device v. Combined oral contraceptives
                  vi. Use of a condom plus oral or injectable or implantable or intrauterine
                  contraception

                  c. These requirements do not apply to participants in a same sex relationship.

               7. Male patients must agree not to donate sperm starting at screening and continuing
                  throughout the clinical study period, and for 90 days after last study drug
                  administration.

               8. Female patients of childbearing potential and their spouse/partner(s):

                    1. Must agree not to become pregnant during the clinical study period and for
                       30 days after last study drug administration.

                    2. Must have a negative serum pregnancy test at screening.

                    3. If heterosexually active, must agree to consistently use a form of highly
                       effective contraception, starting at screening and continuing throughout the
                       clinical study period, and for 30 days after last study drug administration.
                       Highly effective contraception is defined as follows:

                  i. Injectable or implantable hormones ii. Intrauterine device iii. Surgical
                  sterilisation iv. Sterilisation implant device v. Surgical sterilisation of the
                  male partner vi. Combined oral contraceptives vii. Use of a condom plus oral or
                  injectable or implantable or intrauterine contraception

                  Or

                  d. Must agree to stay abstinent (where abstinence is the preferred and usual
                  life-style of the patient), starting at screening and continuing throughout the
                  clinical study period, and for 30 days after last study drug administration.

                  e. These requirements do not apply to participants in a same sex relationship.

               9. Female patients of non-childbearing potential:

                    1. Must have a confirmed clinical history of sterility (e.g. the patient is
                       without a uterus).

                       Or

                    2. Must be postmenopausal as defined as amenorrhea for at least 1 year prior to
                       screening and a laboratory confirmed serum follicle stimulating hormone
                       (FSH) level ≥ 40mIU/mL or similar value considered to be in the menopausal
                       range.

              10. Female patients must agree not to breastfeed from screening, throughout the
                  clinical study period, and until 90 days after last study drug administration.

              11. Female patients must agree not to donate ova from screening, throughout the
                  clinical study period, and until 90 days after last study drug administration.

              12. Patient must be competent to understand the nature of the study and capable of
                  giving written informed consent. Be willing to report for the scheduled study
                  visits and communicate to study personnel about adverse events and concomitant
                  medication use.

              13. Patient agrees not to participate in another interventional study while
                  participating in the present clinical study.

        Exclusion criteria

          1. Female patient who has been pregnant within the 6 months prior to screening or
             breastfeeding within the 3 months prior to screening.

          2. Evidence or history of clinically significant haematological, renal, endocrine,
             pulmonary, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease
             (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies
             and childhood asthma) at time of screening.

          3. Current or chronic history of gastrointestinal illness or conditions interfering with
             normal gastrointestinal anatomy or motility. Examples include gastrointestinal bypass
             surgery, partial or total gastrectomy, small bowel resection, vagotomy, malabsorption,
             Crohn's disease, ulcerative colitis, irritable bowel syndrome (IBS) or celiac sprue.

          4. Evidence or history of gastrointestinal symptoms that could lead to the assumption of
             an underlying gastrointestinal impairment.

          5. Treatment with any anti-platelet and/or anticoagulant medication.

          6. Evidence or history of specific food intolerance. Examples include coeliac disease,
             severe lactose or dairy food intolerance or a severe intolerance to any
             food/ingredient included in the standard breakfast.

          7. Any positive result, on screening, for serum hepatitis B surface antigen (HBsAg),
             hepatitis C virus antibodies (HCV) or antibodies to human immunodeficiency virus type
             1 (HIV-1) and/or type 2 (HIV-2).

          8. A positive drug/alcohol result.

          9. Patient has a history of exceeding &gt; 21 units of alcohol/week for male patients or &gt;
             14 units of alcohol/week for female patients within the 3 months prior to screening.
             One unit of alcohol is equivalent to 5 ounces (150 mL) of wine or 12 ounces (360 mL)
             of beer or 1.5 ounces (45 mL) of spirits.

         10. Patient has a history of regular smoking (daily or most days in a week) or the use of
             nicotine products (3 or more nicotine-containing products) who would be unable to
             abstain from smoking during the confinement periods in the Phase 1 Unit.

         11. Patient has used any recreational drugs of abuse within the 3 months prior to
             screening.

         12. Patient has a pulse rate ≤ 50 or ≥ 100 bpm; mean systolic blood pressure (SBP) &gt; 140
             mmHg; mean diastolic blood pressure (DBP) &gt; 90 mmHg at screening (excluding white-coat
             hypertension; therefore, a repeat test showing results within range will be
             acceptable).

         13. Patient has any clinically significant abnormalities at screening in rhythm,
             conduction or morphology of the resting ECG and any clinically significant
             abnormalities in the 12-lead ECG, as considered by the PI or delegate, which may
             interfere with the interpretation of QTc interval changes including abnormal ST-T wave
             morphology.

         14. Patient has prolonged QTcF (QT interval corrected for heart rate using Fridericia's
             formula) &gt; 450 ms for male patients or &gt; 470 ms for female patients, or a shortened
             QTcF &lt; 300 ms or a family history of prolonged QT syndrome, at screening.

         15. Patient has any clinically significant abnormalities in clinical chemistry,
             haematology, or urinalysis at screening as judged by the PI or delegate, including:
             Aspartate aminotransferase (AST), Alanine aminotransferase (ALT), alkaline phosphatase
             (ALP), gamma glutamyl transferase (GGT) or Total bilirubin (TBL) more than 2.0 times
             above the Upper Limit of Normal (ULN).

         16. Plasma donation within the 14 days prior to screening or any whole blood
             donation/significant blood loss &gt; 500 mL during the 3 months prior to screening.

         17. Treatment with any Investigational Drug or Device/Treatment within the 30 days prior
             to the first administration of study drug.

         18. Use of any prescribed or non-prescribed medication including herbal medicines,
             antacids and analgesics (other than anti-hypertensive drugs, oral contraceptives,
             paracetamol or multi-vitamins) for the two weeks prior to the initial administration
             of the study medication or up to a minimum of 5 times the half-life of the medication
             if it has a long half-life.

         19. Known allergy or adverse reaction history to any of the oral dose formulation
             components e.g. mannitol.

         20. Use of Sapropterin (KUVAN) or pegylated phenylalanine ammonia lyase (Palinzyk) or
             SYNB1618 or any Phenylalanine-lowering drug within the last 4 weeks.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damon Bell</last_name>
    <role>Principal Investigator</role>
    <affiliation>Linear Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tim Heise</last_name>
    <role>Principal Investigator</role>
    <affiliation>Profil Institut für Stoffwechselforschung GmbH</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monika Tadi, PhD</last_name>
    <phone>+41 21 924 45 81</phone>
    <email>monika.tadi@nestle.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Maryam Olesen</last_name>
    <phone>+41 21 924 45 81</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Linear Clinical Research Ltd</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sam Salman, Dr.</last_name>
      <phone>+61 8 6382 5100</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Profil Institut für Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr. Hans-Veit Coester</last_name>
      <phone>+49 2131 4018 408</phone>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 3, 2019</study_first_submitted>
  <study_first_submitted_qc>September 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 11, 2019</study_first_posted>
  <last_update_submitted>January 27, 2020</last_update_submitted>
  <last_update_submitted_qc>January 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Phenylketonurias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

